Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
paliperidone palmitate
|
| gptkbp:approvalYear |
2021
|
| gptkbp:associatedWith |
gptkb:Invega_Sustenna
gptkb:Invega_Trinza |
| gptkbp:ATCCode |
N05AX13
|
| gptkbp:brand |
paliperidone palmitate
|
| gptkbp:contraindication |
hypersensitivity to paliperidone
|
| gptkbp:dosingInterval |
every 6 months
|
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:form |
extended-release
|
| gptkbp:halfLife |
84-139 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Invega Hafyera
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
injection site reaction
weight gain drowsiness extrapyramidal symptoms increased prolactin |
| gptkbp:usedFor |
gptkb:schizoaffective_disorder
schizophrenia |
| gptkbp:bfsParent |
gptkb:Invega
|
| gptkbp:bfsLayer |
6
|